TABLE 2.
Regression analysis of the association between CYP2C19 genotype and plasma bupropion or its metabolites AUC after adjusting for CYP2B6 genotype (study 1)
| BUP AUC24 (r2 = 0.151) |
OH-BUP AUC24 (r2 = 0.313) |
EB AUC24 (r2 = 0.333) |
TB AUC24 (r2 = 0.317) |
|||||
|---|---|---|---|---|---|---|---|---|
| B (95% CI) | P | B (95% CI) | P | B (95% CI) | P | B (95% CI) | P | |
| CYP2C19 *2 | 134 (26, 243) | 0.016* | 1080 (-11023, 263) | 0.323 | 284 (135, 433) | 0.001* | 1955 (875, 3035) | 0.001* |
| CYP2C19 *17 | −24 (-137, 88) | 0.664 | 1468 (-8093, 744) | 0.200 | −36 (-191, 120) | 0.646 | −493 (-1620, 633) | 0.381 |
| CYP2B6 NM>IM>SM | −13 (-90, 64) | 0.733 | −3144 (-4688, -1600) | 0.001* | −103 (-208, 3) | 0.06 | −630 (-1394, 134) | 0.103 |
AUC24, AUC for 24 hours; CI, confidence interval; IM, intermediate metabolizers; NM, normal metabolizers; SM, Slow metabolizers (Zhu et al., 2012; Benowitz et al., 2013).
*
Indicates statistical significance.